Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Jan;41(1):141-149.
doi: 10.1007/s10545-017-0095-6. Epub 2017 Oct 16.

Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study

Affiliations
Multicenter Study

Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study

Maarten Arends et al. J Inherit Metab Dis. 2018 Jan.

Abstract

Quality of life (QoL) is decreased in patients with Fabry disease (FD). To improve QoL, it is important to understand the influence of FD related characteristics, symptoms, and complications. In this retrospective cohort study we explored the effect of pain (measured by the Brief Pain Inventory), phenotype, treatment, and FD-related complications on QoL. QoL data of Fabry patients as assessed by the EuroQol five dimension questionnaire (EQ-5D) from two international centers of excellence were collected. The aim of this study was to evaluate the effect of sex, phenotype, age, different states of disease severity, pain, and ERT on EQ-5D utilities. For 286 adult FD patients (mean age 42.5 years, 40% men, 60% classical phenotype) 2240 EQ-5Ds were available. QoL is decreased in men as well as women with FD, especially in older men with a classical phenotype. At age 50, utility was lower in men with classical FD compared to those with non-classical disease (β = -0.12, 95% CI: -0.23 - 0.01, p = 0.037) with further difference in the years thereafter. Cardiovascular complications, stroke or transient ischemic attacks, multiple FD-related complications and pain were also associated with decreased utilities. Overall, no change in utility was seen in patients on ERT over a mean follow-up of 6.1 years. FD leads to a decreased QoL compared to the general population. Disease complications and pain both negatively influence QoL. Adequate assessment and treatment of pain as well as improved strategies to prevent disease complications are needed to improve QoL in the FD population.

PubMed Disclaimer

Conflict of interest statement

Maarten Arends and Simon Körver declare that they have no conflict of interest. Marieke Biegstraaten and Carla Hollak have received travel support, honoraria for consultancies, and educational grants from Sanofi Genzyme, Shire HGT, Protalix, Actelion, and Amicus. All financial arrangements are made with the AMC Medical Research BV, in accordance with the AMC Research Code. Derralynn Hughes has received honoraria for speaking and advisory boards and support for research from Shire HGT, Sanofi Genzyme, Amicus, and Protalix. Also, Deralynn Hughes has a consultancy arrangement through UCL Consultants (London, United Kingdom) to support, in part, laboratory research. Atul Mehta has received honoraria for consultancy and educational activities as well as research grant support from Shire HGT, Sanofi Genzyme, Protalix/Pfizer, and Amicus.

Figures

Fig. 1
Fig. 1
Relation between EQ-5D and age. Polynomial mixed effect model of EQ-5D in relation to age, stratified for sex and phenotype. Large lines represent fitted values at group level, the smaller lines represent the fitted values at individual patient level

References

    1. Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. 2015;1852:615–621. doi: 10.1016/j.bbadis.2014.06.031. - DOI - PubMed
    1. Arends M, Hollak CE, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015;10:77. doi: 10.1186/s13023-015-0296-8. - DOI - PMC - PubMed
    1. Arends Maarten, Wanner Christoph, Hughes Derralynn, Mehta Atul, Oder Daniel, Watkinson Oliver T., Elliott Perry M., Linthorst Gabor E., Wijburg Frits A., Biegstraaten Marieke, Hollak Carla E. Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. Journal of the American Society of Nephrology. 2016;28(5):1631–1641. doi: 10.1681/ASN.2016090964. - DOI - PMC - PubMed
    1. Biegstraaten M, Hollak CE, Bakkers M, Faber CG, van Schaik IN. Small fiber neuropathy in Fabry disease. Mol Genet Metab. 2012;106:135–141. doi: 10.1016/j.ymgme.2012.03.010. - DOI - PubMed
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23:129–138. - PubMed

Publication types

MeSH terms